Gilead Sciences to Report Q2 Earnings Amid Analyst Expectations of Loss
Gilead Sciences (GILD) is expected to report a loss per share for its second-quarter earnings in fiscal 2026, with analysts forecasting a significant decline from the previous year's profit. Despite this, GILD has consistently exceeded expectations over the past four quarters and outperformed both the S&P 500 Index and healthcare sector ETFs.
Topics: biopharmaceuticals earnings HIV drugs stock performance